Panagiotis Karagiannis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/698272/publications.pdf

Version: 2024-02-01

36 papers	1,826 citations	394421 19 h-index	377865 34 g-index
36 all docs	36 docs citations	36 times ranked	3241 citing authors

#	Article	IF	Citations
1	Immunotherapy in Advanced Prostate Cancerâ€"Light at the End of the Tunnel?. International Journal of Molecular Sciences, 2022, 23, 2569.	4.1	11
2	Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. Clinical and Experimental Immunology, 2022, 207, 84-94.	2.6	4
3	Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine. Leukemia and Lymphoma, 2022, 63, 2645-2651.	1.3	2
4	Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, highâ€dose cytarabine and mitoxantrone. British Journal of Haematology, 2021, 192, e60-e63.	2.5	3
5	In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. OncoImmunology, 2021, 10, 1966970.	4.6	2
6	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. IScience, 2021, 24, 102752.	4.1	9
7	Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients. Blood Advances, 2020, 4, 5936-5941.	5.2	16
8	Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis. Cancers, 2020, 12, 1678.	3.7	3
9	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. Cancer Cell, 2020, 37, 85-103.e9.	16.8	91
10	Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. Cell, 2019, 176, 757-774.e23.	28.9	117
11	Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. Frontiers in Immunology, 2018, 9, 493.	4.8	14
12	Anti-Folate Receptor-Î± IgE but not IgG Recruits Macrophages to Attack Tumors via TNFÎ±/MCP-1 Signaling. Cancer Research, 2017, 77, 1127-1141.	0.9	58
13	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. Frontiers in Immunology, 2017, 8, 1112.	4.8	17
14	IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Scientific Reports, 2016, 6, 29736.	3.3	52
15	IgG4 Characteristics and Functions in Cancer Immunity. Current Allergy and Asthma Reports, 2016, 16, 7.	5.3	76
16	Three Huntingtonâ€™s Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes. PLoS ONE, 2015, 10, e0126860.	2.5	17
17	[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 741-749.	6.4	5
18	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. OncoImmunology, 2015, 4, e1032492.	4.6	53

#	Article	IF	Citations
19	TGF-Î²-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. Current Biology, 2015, 25, 2899-2914.	3.9	106
20	Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma. Molecular Cancer Therapeutics, 2014, 13, 2769-2783.	4.1	73
21	Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency. MAbs, 2014, 6, 509-522.	5.2	12
22	IgE immunotherapy. MAbs, 2014, 6, 54-72.	5.2	46
23	Evaluating biomarkers in melanoma. Frontiers in Oncology, 2014, 4, 383.	2.8	38
24	Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nature Communications, 2014, 5, 4255.	12.8	140
25	3D InÂVitro Model of a Functional Epidermal Permeability Barrier from Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. Stem Cell Reports, 2014, 2, 675-689.	4.8	97
26	A tool kit for rapid cloning and expression of recombinant antibodies. Scientific Reports, 2014, 4, 5885.	3.3	85
27	IgG4 antibodies and cancer-associated inflammation. OncoImmunology, 2013, 2, e24889.	4.6	28
28	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. Microbiology Spectrum, 2013, 1, .	3.0	4
29	Abstract B65: IgG4 subclass antibodies impair antitumor immunity in melanoma.. , 2013, , .		2
30	IgG4 subclass antibodies impair antitumor immunity in melanoma. Journal of Clinical Investigation, 2013, 123, 1457-1474.	8.2	181
31	Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. Journal of Experimental Medicine, 2012, 209, 935-945.	8.5	212
32	Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunology, Immunotherapy, 2012, 61, 1547-1564.	4.2	55
33	Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma. Critical Reviews in Biomedical Engineering, 2012, 40, 279-294.	0.9	8
34	Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. PLoS ONE, 2011, 6, e19330.	2.5	72
35	Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunology, Immunotherapy, 2009, 58, 915-930.	4.2	117
36	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. , 0, , 75-102.		0